KRAS-mutant NSCLC is moving beyond G12C with RAS(ON), G12D, pan-RAS and combination strategies designed to overcome resistance KRAS Mutant NSCLC in 2026: From G12C Inhibition to RAS(ON), Pan-RAS and Combination Strategies For decades, KRAS was considered one of oncology’s most...
The treatment landscape for KRAS G12C-mutated non–small cell lung cancer (NSCLC) could be approaching a turning point as new phase 3 findings suggest that investigational divarasib (Genentech) may outperform currently approved targeted therapies. With detailed results from the Krascendo 1...
Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced the company will present promising preliminary clinical data from the ongoing Phase 1 portion...
KRAS G12S (c.34_35delinsTC) can lead to false-positive results for KRAS G12C on the AmoyDx PCR panel. Confirmation of the genetic mutation using alternative testing methods, such as NGS, is necessary Abbreviations AmoyDx AmoyDx pan lung cancer PCR panel ARMS amplification...
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer. The oral KRAS G12D inhibitor VS-7375 (Verastem) generated durable responses in...
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial. VS-7375, an investigational oral KRAS G12D ON/OFF inhibitor, demonstrated robust antitumor...
What were the results in colorectal and lung cancers? In third-line and later metastatic CRC, VS-7375 at 900 mg plus an anti-EGFR antibody produced an ORR of 33% (n = 2/6), with 1 response confirmed. At 600 mg plus an...
IntroductionKirsten rat sarcoma viral oncogene homolog (KRAS)-mutant lung cancer is associated with a poor prognosis, underscoring the need for effective pha 1 Introduction Pharmacotherapy for advanced non-small cell lung cancer (NSCLC) has substantially evolved with the advent of personalized medicine,...
Herbert Loong: KRAS G12C in Asia, and Why the Landscape Still Matters Herbert Loong, Advisor at Greater Bay Area International Clinical Trial Institute, shared on LinkedIn:. “Throwback: KRAS G12C in Asia, and why the landscape still matters. In 2020, the...
